NASDAQ:DRRX
Durect Corporation Stock News
$0.92
-0.150 (-14.02%)
At Close: May 14, 2024
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®
11:45am, Friday, 17'th Jan 2020
DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Cla
U.S. FDA panel split over approval of Durect's non-opioid painkiller
07:38pm, Thursday, 16'th Jan 2020The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
12:22pm, Thursday, 16'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Jan. 15)
10X Genomics Inc (NASDAQ...
DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company's common stock today.
DURECT Issues Press Release Highlighting Halt In Stock Ahead Of FDA AdCom Panel To Discuss POSIMIR For Post-Surgical Analgesia
12:00am, Thursday, 16'th Jan 2020Durect shares are trading higher. The stock moved higher following unusual interest in next month's $2.5 call contract.
12:00am, Wednesday, 15'th Jan 2020The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO
10:05pm, Sunday, 12'th Jan 2020
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they under
Durect shares are trading lower. Not seeing any company-specific news to justify the price action.
12:00am, Thursday, 09'th Jan 2020Drug developer dips on failed psoriasis trial
10:28pm, Thursday, 02'nd Jan 2020
Shares of drug developer Durect Corp. shed nearly a third of their value Thursday after the Cupertino company said its headline drug failed a mid-stage clinical trial aimed at people with itchy, scaly
DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
02:00pm, Thursday, 02'nd Jan 2020
DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, a
Mid-Afternoon Market Update: Signet Jewelers Falls Following Wells Fargo Downgrade; Trillium Therapeutics Shares Surge
12:00am, Thursday, 02'nd Jan 2020Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
11:00pm, Wednesday, 01'st Jan 2020
In a final push before the closing of the year, the FDA deemed it fit to clear even long pending ones, including Flexion Therapeutics Inc's (NASDAQ: FLXN ) sNDA for the updation of the label for its o
